TY - CHAP M1 - Book, Section TI - Percutaneous and Other Ablative Therapies for Lung Cancer A1 - Wiesel, Ory A1 - Wee, Jon O. A2 - Sugarbaker, David J. A2 - Bueno, Raphael A2 - Burt, Bryan M. A2 - Groth, Shawn S. A2 - Loor, Gabriel A2 - Wolf, Andrea S. A2 - Williams, Marcia A2 - Adams, Ann Y1 - 2020 N1 - T2 - Sugarbaker’s Adult Chest Surgery, 3e AB - Lung cancer is the leading cause of cancer death for both men and women worldwide.1 The introduction of lung screening programs worldwide has increased the diagnosis of early-stage lung cancer in high-risk populations. Surgical resection remains the gold standard treatment for early-stage lung cancer. Yet, only one-third of patients diagnosed with lung cancer are stage appropriate for surgical therapy.2 Further, the growing number of elderly people in the United States and other Western countries has caused an increase in the number of patients with comorbidities, making primary surgical and curative therapy more complicated. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=1170411323 ER -